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Neural cell adhesion molecule (NCAM/CD56) expression in acute myeloid leukemia (AML) has
been associated with extramedullary leukemia, multidrug resistance, shorter remission and
survival. Recently, Bloomfield et al. published a succinct review of issues surrounding the
AML prognostication and current therapeutics. However, we want to reiterate the prognostic
value and therapeutic potential of CD56 that is frequently expressed in AML as was also
reported by their own group earlier. In addition, novel RUNX1 isoforms contribute in controlling
CD56 expression in AML cells. Anti-CD56 antibody therapy deserves exploration as an arsenal
against AML patients expressing CD56. Relevantly, targeting RNA splicing machinery or RUNX1
isoform-specific siRNA may also become part of future therapeutic strategies for AML with CD56
overexpression.
 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).To the Editor,
Neural cell adhesion molecule (NCAM/CD56) expression
in acute myeloid leukemia (AML) has been associated withextramedullary leukemia and multidrug resistance.
Recently, Do¨hner et al. [1] published a succinct review of
the issues surrounding AML prognostication and current
therapeutics. However, they seem to have missed mention-
ing the prognostic value and therapeutic potential of CD56
that is frequently expressed in AML, as, among others, it
was also reported by Baer et al. [2] earlier (Fig. 1) [2]. Addi-
tionally, novel RUNX1 isoforms contribute to controlling
CD56 expression in AML cells [3]. A plethora of data,
Fig. 1 OS and RFS for patients with AML with t(8;21) with and
without CD56 expression. Note: Adapted from ‘‘Expression of
the neural cell adhesion molecule CD56 is associated with short
remission duration and survival in acute myeloid leukemia with
t(8;21)(q22;q22)” by Baer et al. [2]. AML = acute myeloid
leukemia; OS = overall survival; RFS = relapse-free survival.
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sion in AML confers poor prognosis (shorter remission and
survival) even in patients with t(8;21) [4,5]. The Cancer
Genome Atlas data also support the notion that NCAM
overexpression is associated with shorter overall survival;
median 424 days for high NCAM expression versus 945 days
for low NCAM expression in AML M0/M1 (Alshanqeeti, unpub-
lished data). Hence, we want to reiterate that, among other
markers, CD56 overexpression should also be considered as
a prognostic marker in any upcoming AML risk stratification
model.
Interestingly, targeted therapy with Lorvotuzumab mer-
tansine (LM; or IMGN901), a humanized anti-CD56 antibody
attached to the potent cytotoxic agent DM-1, has produced
promising results in clinical trials involving CD56+ solid
tumors and multiple myeloma, both as a single agent and
in combination with chemotherapy [6,7]. Once bound to
CD56, LM is internalized into a cancer cell and releases
DM-1 to initiate cell death via inhibition of tubulin polymer-
ization. Given that the anti-CD56 antibody was humanized
and the cytotoxic compound chosen was maytansine, a
clinically proven immunotoxin used earlier in Gemtuzumab
Ozogamicin (Myelotarg), LM itself meets important
structural criteria that promise good clinical tolerability
and efficacy. LM deserves exploration as an arsenal againstAML patients expressing CD56, especially for minimal resid-
ual disease clearance.
Relevantly, Gattenloehner et al. [3] showed that CD56
expression by AML cells is positively regulated by RUNX1
p48 and negatively regulated by other splice variants, such
as p30. At the protein level, p48high p30low versus
p48low p30high RUNX1 isoform patterns are the major dis-
criminators between CD56+ and CD56 AML cells, respec-
tively. These results temptingly suggest that tipping the
p48/p30 balance toward a p48low phenotype by targeting
the RNA splicing machinery or applying RUNX1 isoform-
specific siRNAs could become part of future therapeutic
strategies for AML with CD56 overexpression [3].
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